# Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients

> **NCT07430683** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University of Guadalajara** · enrollment: 68 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **DRUG:** Valganciclovir Prophylaxis
- **DIAGNOSTIC_TEST:** Preemptive Therapy (CMV PCR Monitoring)

## Key facts

- **NCT ID:** NCT07430683
- **Lead sponsor:** University of Guadalajara
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07430683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07430683, "Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07430683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*